Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2

References

• Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. (2005). Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154–67
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–81
   PubMed Web of Science ®Google Scholar
• Black AE, Hayes RN, Roth BD, et al. (1999). Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 27:916–23
   PubMed Web of Science ®Google Scholar
• Chang JH, Ly J, Plise E, et al. (2014). Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab Dispos 42:1067–73
   PubMed Web of Science ®Google Scholar
• Chen G, Hu N, Liu L, et al. (2011). Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica 41:494–500
   PubMed Web of Science ®Google Scholar
• Haffner SM. (1998). Management of dyslipidemia in adults with diabetes. Diabetes Care 21:160–78
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Kishimoto S, Shibatani N, et al. (2010). The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin‐induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. J Pharm Pharmacol 62:310–14
   PubMed Web of Science ®Google Scholar
• Hermann M, Christensen H, Reubsaet J. (2005). Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC–tandem MS. Anal Bioanal Chem 382:1242–9
   PubMed Web of Science ®Google Scholar
• Hu N, Xie S, Liu L, et al. (2011). Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39:419–25
   PubMed Web of Science ®Google Scholar
• Istvan ES. (2002). Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 144:S27–32
   PubMed Web of Science ®Google Scholar
• Jia L-L, Zhong Z-Y, Li F, et al. (2014). The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic acid in rats. J Pharmacol Sci 124:468–79
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
   PubMed Web of Science ®Google Scholar
• Kameyama N, Arisawa S, Ueyama J, et al. (2008). Increase in P-glycoprotein accompanied by activation of protein kinase Cα and NF-κB p65 in the livers of rats with streptozotocin-induced diabetes. BBA-Mol Basis Dis 1782:355–60
   PubMed Web of Science ®Google Scholar
• Lennernäs H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–60
   PubMed Web of Science ®Google Scholar
• Li F, Zhang M, Xu D, et al. (2014). Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin 35:792–805
   PubMed Web of Science ®Google Scholar
• Li J, Volpe DA, Wang Y, et al. (2011). Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39:1196–202
   PubMed Web of Science ®Google Scholar
• Liu H, Liu L, Li J, et al. (2012). Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos 40:1104–12
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. (2011). Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575–81
   PubMed Web of Science ®Google Scholar
• Markus G, Kathleen K, Stefan O, et al. (2007). Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 80:607–20
   Web of Science ®Google Scholar
• Mei D, Li J, Liu H, et al. (2012). Induction of multidrug resistance-associated protein 2 in liver, intestine and kidney of streptozotocin-induced diabetic rats. Xenobiotica 42:709–18
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. (2011). Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157–81
   PubMed Web of Science ®Google Scholar
• Nobuo S. (1994). Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 26:1261–8
   PubMedGoogle Scholar
• Sato H, Terasaki T, Okumura K, Tsuji A. (1991). Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res: Dordr 8:563–9
   PubMed Web of Science ®Google Scholar
• Shimojo N, Ishizaki T, Imaoka S, et al. (1993). Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46:621–7
   PubMed Web of Science ®Google Scholar
• Shitara Y, Maeda K, Ikejiri K, et al. (2013). Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45–78
   PubMed Web of Science ®Google Scholar
• Tamai I. (2012). Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 64:508–14
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Liu P-Y, Liao JK. (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14:37–44
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, et al. (2010). Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38:215–22
   PubMed Web of Science ®Google Scholar
• Xu D, Li F, Zhang M, et al. (2014). Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes. Acta Pharmacol Sin 35:1215–25
   PubMed Web of Science ®Google Scholar
• Zhang L-L, Lu L, Jin S, et al. (2011). Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 32:956–66
   PubMed Web of Science ®Google Scholar